DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Orchid Pharma Limited — Press Release

NSE 1 hr ago·24 Oct 2026, 11:36 am

Orchid Pharma

Orchid Pharma has announced a licensing and supply agreement with Laboratorio Libra S.A. This partnership will allow Orchid to supply pharmaceutical products to Libra, expanding its market reach. The company has submitted this information to the stock exchange as required by regulations.

This development is significant for investors as it signals Orchid's strategy to diversify its revenue streams and strengthen its presence in international markets. Such agreements can enhance the company's growth prospects and operational efficiency in the long run.

Investors should monitor the progress of this partnership, including any updates on production timelines and market expansion. The successful execution of this deal could positively impact Orchid's financial performance and stock valuation.